The company remains in a pre-revenue state with operating losses reaching $2.2 million in 2026Q3, driven primarily by intensive R&D expenditures of $1.3 million.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | -100% | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 95.74K | 50.74K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -95.74K | -50.74K | -50.74K | -23.07K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | 0% | -119.98% | - | - | - | - | - | - | - | - |
| Operating Expenses | 6.97M | 4.45M | 9.94M | 14.87M | 12.32M | 4.95M | 4.42M | 5.01M | 898.43K | 1.55M | 69.46K |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 3.39M | 3.03M | 3.48M | 7.42M | 7.12M | 3.64M | 3.35M | 1.31M | 575.03K | 1.27M | 69.46K |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 3.65M | 1.41M | 6.46M | 7.45M | 5.2M | 1.31M | 1.07M | 3.7M | 323.4K | 275.05K | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | -68.06K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -7.03M | -4.5M | -9.94M | -14.87M | -12.32M | -4.95M | -4.42M | -5.01M | -898K | -1.55M | -69.46K |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 54.75% | 33.17% | -20.7% | -148.79% | -11.93% | 11.68% | -457.8% | 41.99% | -2128.75% | - |
| EBITDA | -6.94M | -4.45M | -9.89M | -14.85M | -12.32M | 0 | 0 | 0 | 430 | 0 | 0 |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -66.95% | 55.03% | 33.41% | -20.55% | - | - | - | -100% | - | - | - |
| D&A (Non-Cash Add-back) | 95.74K | 50.74K | 50.74K | 23.07K | 3.55K | 4.95M | 4.42M | 5.01M | 898.43K | 1.55M | 69.46K |
| EBIT | -7.03M | -4.5M | -9.94M | -14.87M | -12.32M | -4.89M | -4.41M | -4.86M | -891K | -1.55M | -69.46K |
| Net Interest Income | -5.64K | -18.03K | -10.1K | -7.69K | -46.48K | -157K | 13.93K | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 8 | 47 | 1.71K | 13.93K | 146.39K | 33.23K | 21.5K | 0 |
| Interest Expense | 4.3K | 18.03K | 10.1K | 7.7K | 46.52K | 158.8K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -6.98K | -18.03K | -10.1K | -7.7K | -42.52K | -94.68K | 13.93K | 146.39K | -33.23K | -21.5K | 0 |
| Pretax Income | -7.04M | -4.51M | -9.95M | -14.88M | -12.36M | -5.05M | -4.41M | -4.86M | -932K | -1.57M | -69.46K |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -7.04M | -4.51M | -9.95M | -14.88M | -12.36M | -5.05M | -4.41M | -4.86M | -932K | -1.57M | -69.46K |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -66.61% | 54.62% | 33.14% | -20.35% | -144.94% | -14.44% | 9.3% | -421.67% | 40.64% | -2160.42% | - |
| Net Income (Continuing) | -7.04M | -4.51M | -9.95M | -14.88M | -12.36M | -5.05M | -4.41M | -4.86M | -932K | -1.57M | -69.46K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.85 | -11.32 | -132.33 | -205.97 | -187.31 | -93.78 | -83.56 | -111.56 | -27.71 | -73.59 | 0.00 |
| EPS Growth % | 83.53% | 91.45% | 35.75% | -9.96% | -99.73% | -12.23% | 25.1% | -302.6% | 62.35% | - | - |
| EPS (Basic) | - | -11.32 | -132.33 | -205.97 | -187.31 | -93.78 | -83.56 | -111.56 | -27.71 | -73.59 | 0.00 |
| Diluted Shares Outstanding | 3.8M | 450.8K | 75.17K | 72.24K | 66K | 53.81K | 52.78K | 43.59K | 33.62K | 21.33K | 0 |
| Basic Shares Outstanding | 3.8M | 398K | 75K | 72K | 65K | 53K | 52K | 43K | 33K | 21K | 0 |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - |
Imminent liquidity and dilution risk
As indicated by the company's financial statements, ALZN has failed to generate meaningful revenue since 2024Q4, confirming its status as a pre-commercial entity where growth is measured solely by clinical trial progression rather than top-line sales, leaving the firm entirely dependent on external capital for survival.
The absence of recurring revenue streams underscores the speculative nature of the investment, as the company lacks any commercialized products to offset its operational costs. Investors should monitor the lack of milestone payments or licensing income, which suggests that the company has yet to validate its therapeutic pipeline through strategic partnerships.
Based on reported figures, the company's cost structure is dominated by R&D expenditures, which reached $1.3 million in 2026Q3, reflecting the high financial burden of maintaining Phase II clinical trials without the support of a commercial revenue base to mitigate the ongoing cash outflow.
The volatility in R&D spending, which fluctuated significantly from $176.3K in 2026Q2 to $1.7 million in 2026Q1, highlights the unpredictable nature of clinical trial expenses. This cost profile suggests that management lacks control over the timing of major expenditures, which may exacerbate the pressure on the company's limited cash reserves.
According to recent SEC filings, ALZN's operating losses remain deeply negative, with a $2.2 million loss reported in 2026Q3, demonstrating that the company has no ability to scale operating income as it continues to prioritize R&D spending over the achievement of any operational efficiency or profitability.
The lack of gross profit, combined with consistent SG&A expenses, indicates that the company is not currently structured to achieve operating leverage. This suggests that any future improvement in the bottom line is entirely contingent upon successful clinical outcomes rather than internal cost rationalization or operational scaling.
As reported in financial statements, the company's net loss of $2.2 million in 2026Q3, coupled with historical stock-based compensation, suggests that shareholders face significant dilution risk as the firm relies on equity issuance to fund its operations in the absence of any sustainable cash-generating activities.
The frequent use of equity to cover operating deficits may lead to substantial per-share value erosion, even if the enterprise value remains relatively stable. Investors should scrutinize the impact of these financing activities, as they may prioritize immediate liquidity needs over the long-term interests of existing equity holders.
Quick answers to the most common questions about buying ALZN stock.
For fiscal year 2025, Alzamend Neuro, Inc. (ALZN) reported total revenue of $0.0M.
Alzamend Neuro, Inc. (ALZN) reported a net loss of $4.5M for the fiscal year ending 2025.